Indeed, a randomized clinical trial is currently testing potential benefit of adding losartan to chemo-radiation and anti-PD1 antibody in locally advanced pancreatic cancer (NCT03563248) [11]. The gene discussed is PDCD1; the disease is familial pancreatic carcinoma.